<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432806</url>
  </required_header>
  <id_info>
    <org_study_id>17-594</org_study_id>
    <nct_id>NCT03432806</nct_id>
  </id_info>
  <brief_title>A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors</brief_title>
  <official_title>Development of Novel Imaging and Laboratory Biomarkers to Monitor the Liver Pre-metastatic Niche and Guide Treatment of Colon Cancer: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore novel ways of diagnosing colon cancer and predicting&#xD;
      its propensity to spread to other organs such as the liver.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>successful isolation of exosomes</measure>
    <time_frame>1 year</time_frame>
    <description>defined as isolation of at least 5μg of exosomal protein and reported as a binomial proportion with a 95% confidence interval.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Liver Tumors</condition>
  <arm_group>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draws</intervention_name>
    <description>Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.</description>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colectomy or hepatectomy</intervention_name>
    <description>Three small pieces of otherwise &quot;normal-appearing&quot; liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected.</description>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fibroscan test</intervention_name>
    <description>This may be done either at a preoperative clinic setting or immediately prior to surgery.</description>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSK clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be undergoing one of the following procedures as part of their routine&#xD;
             care in order to meet the inclusion criteria:&#xD;
&#xD;
               -  Operation for presumed stage I-IV colon cancer including colectomy, hepatectomy,&#xD;
                  or abdominal surgery (e.g. insertion of HAIP)&#xD;
&#xD;
               -  Colectomy for presumed benign or pre-malignant colon tumors (e.g. large&#xD;
                  nonneoplastic polyps or adenomas)&#xD;
&#xD;
          -  Open, laparoscopic, or robotic resections&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extrahepatic CRC metastasis&#xD;
&#xD;
          -  No preoperative portal venous phase CT scan performed up to two months prior to day of&#xD;
             surgery Pathology demonstrating a malignant tumor other than colorectal&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  Stage IV colon cancer with resectable hepatic disease undergoing hepatectomy with&#xD;
             active primary colon tumor still in place (despite chemo-radiation therapy) and no&#xD;
             plans for colectomy.&#xD;
&#xD;
          -  Receipt of experimental therapies for colon cancer (e.g. checkpoint inhibitors or&#xD;
             novel targeted agents). Of note, approved targeted agents (such as anti-angiogenic&#xD;
             agents, EGFR inhibitors etc) are not an exclusion criterion.&#xD;
&#xD;
          -  History of non-colonic malignancy w/in 5 years (except non-melanomatous skin cancer)&#xD;
&#xD;
          -  Colon cancer with microsatellite instability (MSI-high) if known preoperatively&#xD;
&#xD;
          -  Known hereditary colon cancer syndrome such as familial adenomatous polyposis (FAP) or&#xD;
             hereditary nonpolyposis colorectal cancer (HNPCC)&#xD;
&#xD;
          -  Known liver disease (e.g. non-alcoholic steatohepatitis, cirrhosis, viral or other&#xD;
             form of hepatitis, etc)&#xD;
&#xD;
          -  INR &gt;2 or known clotting factor deficiency&#xD;
&#xD;
          -  Anticipated need for full anticoagulation during hospitalization&#xD;
&#xD;
          -  Receipt of medications that increase significantly the risk of bleeding after liver&#xD;
             biopsy (at the surgeon&quot;s discretion)&#xD;
&#xD;
          -  Intraoperative discovery of pathology that precludes the planned surgical resection or&#xD;
             liver biopsy, or makes resection futile (such as peritoneal carcinomatosis or other&#xD;
             extrahepatic metastatic disease)&#xD;
&#xD;
          -  Operating surgeon deems research interventions to be more than a minimal risk for the&#xD;
             patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D'Angelica</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael D'Angelica, MD</last_name>
    <phone>212-639-3226</phone>
    <email>dangelim@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Wieser, MD</last_name>
    <phone>212-639-6698</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
    <contact_backup>
      <last_name>Martin Weiser, MD</last_name>
      <phone>212-639-6698</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue samples</keyword>
  <keyword>17-594</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

